Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11551590 | 0.93 | TSHR (0.42) | TSHRADRB2ADRB1ADRB3ATM | |
| SCHEMBL9242453 | 0.88 | HTT (0.40) | TSHRCYP3A4ALDH1A1 | |
| SCHEMBL11040216 | 0.87 | HSD17B10 (0.33) | HSD17B10 | |
| SCHEMBL20239708 | 0.86 | TSHR (0.33) | TSHRADRB2ADRB1ADRB3ATM | |
| SCHEMBL20239689 | 0.85 | TSHR (0.37) | TSHRADRB2ADRB1ADRB3CYP3A4 | |
| SCHEMBL5091619 | 0.84 | HTT (0.45) | TSHRALDH1A1 | |
| SCHEMBL6903306 | 0.84 | HTT (0.45) | TSHRALDH1A1 | |
| SCHEMBL10493858 | 0.79 | TSHR (0.39) | TSHRADRB2ADRB1ADRB3ATM | |
| SCHEMBL20239702 | 0.79 | THRB (0.41) | TSHRALDH1A1 | |
| SCHEMBL20239827 | 0.79 | THRB (0.41) | TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050026908-A1 | Carboxylic acid derivatives, processes for the preparation thereof and pharmaceutical aggents comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2005-02-03 | — | — | US | disclosed |
| US-6835752-B2 | Can bind to Prostaglandin E2 receptors, especially, EP3 receptor and/or EP4 receptor and show antagonizing activity, and may be useful for prevention and/or treatment of disease, for example, pain, allergy, Alzheimer's disease, cancer | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-12-28 | — | — | US | disclosed |
| US-20040235825-A1 | Carboxylic acid derivatives, processes for the preparation thereof and pharmaceutical agents comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2004-11-25 | — | — | US | disclosed |
| US-20040002493-A1 | Benzoic acid derivatives and pharmaceutical agents comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-01-01 | — | — | US | disclosed |
| US-20030216381-A1 | Carboxylic acid derivatives, process for producing the same and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-11-20 | — | — | US | disclosed |
| EP-1314719-A1 | BENZOIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-05-28 | — | — | EP | disclosed |
| EP-1312601-A1 | CARBOXYLIC ACID DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-05-21 | — | — | EP | disclosed |
| EP-0559859-A1 | FLUOROBENZONITRILES AND LIQUID CRYSTALLINE MIXTURES CONTAINING THEM | MERCK PATENT GmbH (DE) | 1993-09-15 | — | — | EP | disclosed |
| WO-1993007136-A1 | FLUOROBENZONITRILES AND LIQUID CRYSTALLINE MIXTURES CONTAINING THEM | F. HOFFMANN-LA ROCHE AG (CH) | 1993-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026908-A1 | Carboxylic acid derivatives, processes for the preparation thereof and pharmaceutical aggents comprising the same as active ingredient | PTGER4, PTGER3, LTB4R | TSHR 2539/4885ADRB2 778/4885ADRB1 531/4885 |
| US-20040235825-A1 | Carboxylic acid derivatives, processes for the preparation thereof and pharmaceutical agents comprising the same as active ingredient | PTGER4, PTGER1, LTB4R | TSHR 2511/4885ADRB2 416/4885ADRB1 306/4885 |
| US-20040002493-A1 | Benzoic acid derivatives and pharmaceutical agents comprising the same as active ingredient | PTGER1, PTGER4, PTGES | TSHR 3226/4885ADRB2 367/4885ADRB1 250/4885 |
| US-20030216381-A1 | Carboxylic acid derivatives, process for producing the same and drugs containing the same as the active ingredient | PTGER4, PTGER1, PTGER2 | TSHR 2553/4885ADRB2 393/4885ADRB1 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.